MLTX — Moonlake Immunotherapeutics
In 2026 Q2, 3 of the 140 tracked hedge funds reported a position in Moonlake Immunotherapeutics (MLTX), worth $15.10M combined. Over the quarter 3 opened or added, 0 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| Renaissance | $12.52M | 0.02% | +132.4% |
| Quadrature | $2.13M | 0.02% | NEW |
| IMC | $448.75K | 0.00% | +103% |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.